A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor.
In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval.
The firm does not have specific management team requirements and does not require to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Author: Next Phase Admin
Hot Investor Mandate: European Investment Firm Seeks Innovative Therapeutics Opportunities, Investing Up to €20M Over the Company’s Lifecycle
A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team in Spain that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm has over €400M million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments.
The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.
The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Family Office Fund Invests in North American Companies in the Intersection of Technology of Life Science, Such as AI-Enabled Drug Discovery Platforms
A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.
The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.
The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Announcing Family Office BioForum at RESI Boston September 2023
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
RESI Boston September will feature the Family Office BioForum, for both sourcing assets and identifying syndication partners bridging the gap between family offices and investment opportunities within the life sciences sector. The Family Office BioForum will feature an open-to-the-public Family Office Panel as part of the RESI program and an invitation-only luncheon discussing early-stage investment topics, including souring technology assets, identifying syndicate opportunities, and finding the right investment funds.
As the life sciences sector continues to burgeon with groundbreaking discoveries, therapies, and technologies, the need for early capital injection becomes ever more pronounced. The Family Office BioForum is a convergence point where family offices can simultaneously identify promising startups and collaborate with other like-minded investors.
The Power of Syndication
Syndication has emerged as a dynamic strategy in the investment landscape, offering distinct advantages to family offices and entrepreneurs seeking funding. Family offices can diversify risk and share due diligence efforts by joining forces with other investors in a syndicate. This collaborative approach allows investors to tap into a broader range of investment opportunities and capitalize on their combined expertise. Conversely, entrepreneurs benefit from access to a syndicate’s collective knowledge and resources, expediting fundraising and enhancing their chances of securing the necessary funds.
The Family Office Factor
Family offices are known for their long-term investment outlook and commitment to fostering meaningful impact. With a mission to preserve and grow their wealth across generations, family offices are uniquely positioned to contribute to the life sciences sector. Their involvement goes beyond monetary support; it encompasses mentorship, guidance, and a vested interest in the success of the ventures they invest in. The Global Family Office BioForum acknowledges this distinctive role and seeks to create an environment where family offices can connect with like-minded syndicate partners and explore transformative investment opportunities.
| For more information on the Family Office BioForum | Click here |
| If you are a Family Office and would like to attend the Family Office BioForum Luncheon | Click here |
Partnering Opens for RESI Boston Next Week
By Karen Deyo, Director of Product, Israel BD, LSN
Partnering for RESI Boston September, a hybrid event (in-person on September 18, or virtually on September 19-20) launches next Monday, giving registered attendees access to RESI’s unique partnering platform. This platform allows attendees to filter search results with a high degree of precision.
At RESI, unlike other conferences, requesting a meeting with an investor does not require a company to spend most of the initial meeting finding out if they are a fit for the investor or not. Companies can easily determine a list of investors who are interested in their sector, indication, and stage of development before requesting a meeting. Investor profiles are written by Life Science Nation (LSN)’s Investor Research team in a phone interview with each investor, as a requirement before registration.
The RESI Partnering Platform has an integrated video conferencing system, allowing companies to simply log in to the platform and initiate their meetings through their schedule. Make sure to look at the tutorial video below, to see all the features offered by our system!
Premier Platform Sample
Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!
LSN Announces Collaboration with Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at RESI Boston in September
By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.
As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:
- Nutrition
- Polyphenols to treat chronic diseases
- Robotic intramuscular injections
- Wearable artificial kidney for ambulatory dialysis
- Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
- Electronic medical records
- Non-viral and re-dosable gene therapies
These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.
With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.
Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!
Hot Investor Mandate: USA-Based Investment Firm Makes Both Venture & Growth Stage Investments, Focusing Exclusively on Therapeutics
Frazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA. The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016. Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies. Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment. While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe. In addition to growth and venture-stage investments, Frazier also engages in company creation. The firm is a lead investor in most of its deals.
Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.
Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 